Abstract

Chimeric Antigen Receptor (CAR) T cell therapy has revolutionized cancer treatment, particularly for hematologic malignancies. However, challenges such as limited efficacy in solid tumors and antigen escape have prompted the development of novel approaches. One such innovation is the STAb (Synthetic T-cell Activating Bifunctional) CAR-T cells, which aim to enhance the therapeutic potential of CAR-T cells. This review will investigate the functioning, benefits, clinical trials, obstacles, and future prospects of STAb CAR-T cells, underscoring their transformative potential in cancer treatment.

Keywords

STAb CAR-T Cells